Mibefradil, a non-selective calcium channel blocker, inhibited the non-homologous end-joining (NHEJ) repair system and the T-type calcium channel, CAV3.2, a molecule upregulated in certain GBM patients that have worse prognosis [43]. The gene discussed is CACNA1H; the disease is glioblastoma.